Legal & General Group
HRTX icon

Legal & General Group’s Heron Therapeutics HRTX Stock Holding History

Legal & General Group’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$11.1K Sell
13,930
-307
-2% -$356 ﹤0.01% 3155
2025
Q4 		$18.5K Hold
14,237
– – ﹤0.01% 3058
2025
Q3 		$17.9K Hold
14,237
– – ﹤0.01% 3087
2025
Q2 		$29.5K Buy
14,237
+3,805
+36% +$7.77K ﹤0.01% 2858
2025
Q1 		$22.9K Hold
10,432
– – ﹤0.01% 2898
2024
Q4 		$16K Hold
10,432
– – ﹤0.01% 3109
2024
Q3 		$20.8K Hold
10,432
– – ﹤0.01% 3036
2024
Q2 		$36.5K Sell
10,432
-211
-2% -$648 ﹤0.01% 2838
2024
Q1 		$29.5K Hold
10,643
– – ﹤0.01% 2859
2023
Q4 		$18.1K Sell
10,643
-1,190
-10% -$1.31K ﹤0.01% 3071
2023
Q3 		$12.2K Hold
11,833
– – ﹤0.01% 3227
2023
Q2 		$13.7K Sell
11,833
-8,404
-42% -$15K ﹤0.01% 3258
2023
Q1 		$30.6K Sell
20,237
-24,108
-54% -$60.4K ﹤0.01% 2958
2022
Q4 		$111K Sell
44,345
-1,193
-3% -$3.84K ﹤0.01% 2797
2022
Q3 		$192K Sell
45,538
-28,809
-39% -$113K ﹤0.01% 2646
2022
Q2 		$208K Buy
74,347
+1,114
+2% +$4.47K ﹤0.01% 2612
2022
Q1 		$418K Buy
73,233
+1,187
+2% +$8.69K ﹤0.01% 2439
2021
Q4 		$658K Buy
72,046
+221
+0.3% +$2.26K ﹤0.01% 2336
2021
Q3 		$768K Buy
71,825
+18,527
+35% +$226K ﹤0.01% 2310
2021
Q2 		$827K Hold
53,298
– – ﹤0.01% 2242
2021
Q1 		$864K Buy
53,298
+532
+1% +$9.48K ﹤0.01% 2219
2020
Q4 		$1.12M Sell
52,766
-116
-0.2% -$2.02K ﹤0.01% 2079
2020
Q3 		$783K Sell
52,882
-3,828
-7% -$59.7K ﹤0.01% 2097
2020
Q2 		$835K Buy
56,710
+13,627
+32% +$224K ﹤0.01% 2035
2020
Q1 		$505K Sell
43,083
-3,702
-8% -$69.6K ﹤0.01% 2062
2019
Q4 		$1.1M Buy
46,785
+6,045
+15% +$134K ﹤0.01% 2040
2019
Q3 		$754K Buy
40,740
+11,556
+40% +$213K ﹤0.01% 2077
2019
Q2 		$543K Buy
29,184
+1,332
+5% +$26.6K ﹤0.01% 2127
2019
Q1 		$680K Buy
27,852
+288
+1% +$7.54K ﹤0.01% 2087
2018
Q4 		$716K Buy
27,564
+1,679
+6% +$46.2K ﹤0.01% 2012
2018
Q3 		$819K Buy
25,885
+15,599
+152% +$581K ﹤0.01% 2008
2018
Q2 		$400K Buy
10,286
+229
+2% +$7.29K ﹤0.01% 2158
2018
Q1 		$277K Sell
10,057
-1,315
-12% -$29.8K ﹤0.01% 2240
2017
Q4 		$208K Sell
11,372
-218
-2% -$3.56K ﹤0.01% 2303
2017
Q3 		$186K Buy
11,590
+236
+2% +$3.7K ﹤0.01% 2365
2017
Q2 		$157K Buy
11,354
+2,383
+27% +$34.5K ﹤0.01% 2393
2017
Q1 		$136K Buy
8,971
+1,098
+14% +$15.2K ﹤0.01% 2399
2016
Q4 		$102K Buy
7,873
+4,000
+103% +$62.8K ﹤0.01% 2552
2016
Q3 		$66K Sell
3,873
-338
-8% -$6.27K ﹤0.01% 2395
2016
Q2 		$75K Hold
4,211
– – ﹤0.01% 2254
2016
Q1 		$83K Sell
4,211
-79
-2% -$1.56K ﹤0.01% 2160
2015
Q4 		$118K Hold
4,290
– – ﹤0.01% 1980
2015
Q3 		$95K Hold
4,290
– – ﹤0.01% 2070
2015
Q2 		$130K Buy
+4,290
New +$80.7K ﹤0.01% 1944

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

Legal & General Group's HRTX Position: Q1 2026 in Review

Legal & General Group reduced its Heron Therapeutics (HRTX) stake by 2.2% in Q1 2026, selling an estimated $356 and leaving 13,930 shares worth $11.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3155.

Legal & General Group first reported a position in HRTX in Q2 2015 and has held it in 44 quarters since. The position peaked at $1.12M in Q4 2020. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • Legal & General Group held 13,930 shares of Heron Therapeutics worth $11.1K as of Q1 2026.
  • Legal & General Group sold 307 Heron Therapeutics shares in Q1 2026, an estimated $356.
  • Heron Therapeutics made up ﹤0.01% of Legal & General Group's portfolio in Q1 2026, its #3155 holding.
  • Legal & General Group first reported a position in Heron Therapeutics in Q2 2015 and has held it in 44 quarters since.
  • Legal & General Group's Heron Therapeutics position peaked at $1.12M in Q4 2020.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on Legal & General Group's 13F filing for Q1 2026, filed 8 May 2026.